Valganciclovir and bevacizumab for recurrent glioblastoma: A single-institution experience

Peng,Chengwei; Wang,Jialing; Tanksley,Jarred  P.; Mobley,Bret  C.; Ayers,Gregory  D.; Moots,Paul  L.; Clark,Stephen  W.

doi:10.3892/mco.2015.692

February-2016 Volume 4 Issue 2

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

February-2016 Volume 4 Issue 2

Full Size Image

Article

Valganciclovir and bevacizumab for recurrent glioblastoma: A single-institution experience

Authors:
- Chengwei Peng
- Jialing Wang
- Jarred P. Tanksley
- Bret C. Mobley
- Gregory D. Ayers
- Paul L. Moots
- Stephen W. Clark
View Affiliations / Copyright

Affiliations: Department of Neurology, Vanderbilt University School of Medicine, Nashville, TN 37232, USA, Department of Neurosurgery, Vanderbilt University School of Medicine, Nashville, TN 37232, USA, Department of Pathology, Vanderbilt University School of Medicine, Nashville, TN 37232, USA, Center for Quantitative Sciences, Vanderbilt University School of Medicine, Nashville, TN 37232, USA
Pages: 154-158
|
Published online on: December 4, 2015

https://doi.org/10.3892/mco.2015.692
Expand metrics +

Abstract

Prolonged treatment with adjuvant valganciclovir has been shown in one retrospective study to exert a significant effect on overall survival (OS) in newly diagnosed patients with glioblastoma multiforme (GBM). However, studies evaluating the effectiveness of valganciclovir in the treatment of recurrent GBM have not been performed. We evaluated the effect of valganciclovir in the recurrent setting in combination with bevacizumab therapy. A retrospective analysis was performed on patients treated for recurrent GBM with off‑label valganciclovir and bevacizumab at Vanderbilt University. We identified 13 patients who received valganciclovir plus bevacizumab at some point during their treatment, 8 of whom were started on valganciclovir and bevacizumab concurrently upon first recurrence, whereas 5 had valganciclovir added to their bevacizumab regimen prior to a second recurrence. of these patients, 12 were pathologically confirmed to have GBM, and 1 patient was diagnosed with gliosarcoma. We also identified an institutional cohort of 50 patients who had not been exposed to valganciclovir, but were treated with bevacizumab for first recurrence. The progression‑free survival (PFS) at 6 months (PF6) and median OS (mOS) in the valganciclovir plus bevacizumab group was 62% and 13.1 months, respectively, for all 13 patients, and 50% and 11.3 months, respectively, for the 8 concurrently treated patients. In the institutional bevacizumab cohort, the PF6 and mOS were 34% and 8.7 months, respectively. In this retrospective analysis, valganciclovir in combination with bevacizumab exhibited a trend toward improved survival in patients with recurrent GBM. However, given the small sample size and the retrospective nature of this study, a larger prospective study is required to confirm these results.

View Figures

View References

1	Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, et al: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 352:987–996. 2005. View Article : Google Scholar : PubMed/NCBI
2	Stragliotto G, Rahbar A, Solberg NW, Lilja A, Taher C, Orrego A, Bjurman B, Tammik C, Skarman P, Peredo I and Söderberg-Nauclér C: Effects of valganciclovir as an add-on therapy in patients with cytomegalovirus-positive glioblastoma A randomized, double-blind, hypothesis-generating study. Int J Cancer. 133:1204–1213. 2013. View Article : Google Scholar : PubMed/NCBI
3	Söderberg-Nauclér C, Rahbar A and Stragliotto G: Survival in patients with glioblastoma receiving valganciclovir. N Engl J Med. 369:985–986. 2013. View Article : Google Scholar : PubMed/NCBI
4	Cobbs CS, Harkins L, Samanta M, Gillespie GY, Bharara S, King PH, Nabors LB, Cobbs CG and Britt WJ: Human cytomegalovirus infection and expression in human malignant glioma. Cancer Res. 62:3347–3350. 2002.PubMed/NCBI
5	Rahbar A, Stragliotto G, Orrego A, Peredo I, Taher C, Willems J and Söderberg-Naucler C: Low levels of human cytomegalovirus infection in glioblastoma multiforme associates with patient survival; -a case-control study. Herpesviridae. 3:32012. View Article : Google Scholar : PubMed/NCBI
6	Bhattacharjee B, Renzette N and Kowalik TF: Genetic analysis of cytomegalovirus in malignant gliomas. J Virol. 86:6815–6824. 2012. View Article : Google Scholar : PubMed/NCBI
7	Baumgarten P, Michaelis M, Rothweiler F, Starzetz T, Rabenau HF, Berger A, Jennewein L, Braczynski AK, Franz K, Seifert V, et al: Human cytomegalovirus infection in tumor cells of the nervous system is not detectable with standardized pathologico-virological diagnostics. Neuro Oncol. 16:1469–1477. 2014. View Article : Google Scholar : PubMed/NCBI
8	Hellstrand K, Martner A and Bergström T: Valganciclovir in patients with glioblastoma. N Engl J Med. 369:20662013. View Article : Google Scholar : PubMed/NCBI
9	Ranganathan P, Clark PA, Kuo JS, Salamat MS and Kalejta RF: Significant association of multiple human cytomegalovirus genomic loci with glioblastoma multiforme samples. J Virol. 86:854–864. 2012. View Article : Google Scholar : PubMed/NCBI
10	Liu CJ and Hu YW: Immortal time bias in retrospective analysis, Is there a survival benefit in patients with glioblastoma who received prolonged treatment of adjuvant valganciclovir? Int J Cancer. 135:250–251. 2014. View Article : Google Scholar : PubMed/NCBI
11	Söderberg-Naucler C, Peredo I, Rahbar A, Hansson F, Nordlund A and Stragliotto G: Use of Cox regression with treatment status as a time-dependent covariate to re-analyze survival benefit excludes immortal time bias effect in patients with glioblastoma who received prolonged adjuvant treatment with valganciclovir. Int J Cancer. 135:248–249. 2014. View Article : Google Scholar : PubMed/NCBI
12	Nghiemphu PL, Liu W, Lee Y, Than T, Graham C, Lai A, Green RM, Pope WB, Liau LM, Mischel PS, et al: Bevacizumab and chemotherapy for recurrent glioblastoma: A single-institution experience. Neurology. 72:1217–1222. 2009. View Article : Google Scholar : PubMed/NCBI
13	Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE, Yung WK, Paleologos N, Nicholas MK, Jensen R, et al: Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol. 27:4733–4740. 2009. View Article : Google Scholar : PubMed/NCBI
14	Cobbs CS: Cytomegalovirus and brain tumor: Epidemiology, biology and therapeutic aspects. Curr Opin Oncol. 25:682–688. 2013. View Article : Google Scholar : PubMed/NCBI
15	Garcia-Manero G and Fenaux P: Hypomethylating agents and other novel strategies in myelodysplastic syndromes. J Clin Oncol. 29:516–523. 2011. View Article : Google Scholar : PubMed/NCBI

Journals

International Journal of Molecular Medicine

International Journal of Oncology

Molecular Medicine Reports

Oncology Reports

Experimental and Therapeutic Medicine

Oncology Letters

Biomedical Reports

Molecular and Clinical Oncology

World Academy of Sciences Journal

International Journal of Functional Nutrition

International Journal of Epigenetics

Medicine International

Valganciclovir and bevacizumab for recurrent glioblastoma: A single-institution experience

This article is mentioned in:

Abstract

Figure 1

Figure 2

Related Articles